mRNA cancer vaccines: Advances, trends and challenges.
10.1016/j.apsb.2022.03.011
- Author:
Qing HE
1
;
Hua GAO
1
;
Dejiang TAN
1
;
Heng ZHANG
1
;
Jun-Zhi WANG
1
Author Information
1. National Institutes for Food and Drug Control, State Key Laboratory for Evaluation and Standardization of Innovative Vaccines and Biotechnology Products, Beijing 102629, China.
- Publication Type:Review
- Keywords:
Adjuvants;
Administration routes;
Cancer vaccine;
Neoantigens;
Tumor-associated antigens;
mRNA;
mRNA delivery vectors
- From:
Acta Pharmaceutica Sinica B
2022;12(7):2969-2989
- CountryChina
- Language:English
-
Abstract:
Patients exhibit good tolerance to messenger ribonucleic acid (mRNA) vaccines, and the choice of encoded molecules is flexible and diverse. These vaccines can be engineered to express full-length antigens containing multiple epitopes without major histocompatibility complex (MHC) restriction, are relatively easy to control and can be rapidly mass produced. In 2021, the U.S. Food and Drug Administration (FDA) approved the first mRNA-based coronavirus disease 2019 (COVID-19) vaccine produced by Pfizer and BioNTech, which has generated enthusiasm for mRNA vaccine research and development. Based on the above characteristics and the development of mRNA vaccines, mRNA cancer vaccines have become a research hotspot and have undergone rapid development, especially in the last five years. This review analyzes the advances in mRNA cancer vaccines from various perspectives, including the selection and expression of antigens/targets, the application of vectors and adjuvants, different administration routes, and preclinical evaluation, to reflect the trends and challenges associated with these vaccines.
